Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-09
2007-01-09
Tucker, Zachary C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S350000
Reexamination Certificate
active
10776631
ABSTRACT:
This invention pertains to compounds of Formula I:and the pharmaceutically-acceptable forms thereof.The variables R1, R2, R3, Z1, Z2, W, and X shown in Formula I are defined herein.The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents.The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to Hsp90 complex modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including chronic myeloid leukemia, melanoma, breast, ovarian, brain, thyroid, colorectal, prostate, and bladder cancer, heart disease, stroke, autoimmune/inflammatory diseases, and neurodegenerative diseases. Thus methods of treatment include administering a sufficient amount of a compound of Formula I or form thereof to decrease the symptoms or slow the progression of these diseases or disorders.The invention also encompasses methods of treating non-human patients, including livestock and domesticated companion animals, suffering from a disease or disorder responsive to Hsp90 complex modulation.Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agent.The invention also includes a method for determining the presence of certain kinases or Hsp90 complex in a sample, comprising contacting the sample with a compound of Formula I or form thereof, and detecting Hsp9O complex activity in the sample.
REFERENCES:
patent: 5593997 (1997-01-01), Dow et al.
patent: 5658857 (1997-08-01), Andree et al.
patent: 5783576 (1998-07-01), Roos et al.
patent: 6919341 (2005-07-01), Paruch et al.
patent: 2003/0212073 (2003-11-01), Currie et al.
patent: 2004/0063715 (2004-04-01), Paruch et al.
patent: 2004/0067951 (2004-04-01), DeSimone et al.
patent: 2004/0072835 (2004-04-01), Paruch et al.
patent: 2004/0220189 (2004-11-01), Sun et al.
patent: 2005/0009832 (2005-01-01), Sun et al.
patent: 2005/0054648 (2005-03-01), Mitchell et al.
patent: 2005/0085484 (2005-04-01), Mitchell et al.
patent: 2005/0090499 (2005-04-01), Currie et al.
patent: 2005/0101604 (2005-05-01), Currie et al.
patent: 2005/0288295 (2005-12-01), Currie et al.
patent: 43 37 609 (1995-05-01), None
patent: 0 480 713 (1992-04-01), None
patent: WO 88/04298 (1988-06-01), None
patent: WO 95/12594 (1995-05-01), None
patent: WO 96/04298 (1996-02-01), None
patent: WO 96/34866 (1996-11-01), None
patent: WO 99/28322 (1999-06-01), None
patent: WO 01/27119 (2001-04-01), None
patent: WO 02/10170 (2002-02-01), None
patent: WO 02/30428 (2002-04-01), None
patent: WO 02/060492 (2002-08-01), None
patent: WO 02/066481 (2002-08-01), None
patent: WO 02/076985 (2002-10-01), None
patent: WO 03/070732 (2003-08-01), None
patent: WO 2003/089434 (2003-10-01), None
patent: WO 2004/022562 (2004-03-01), None
patent: WO 2004/026310 (2004-04-01), None
patent: WO 2004/026877 (2004-04-01), None
patent: WO 2004/072080 (2004-08-01), None
patent: WO 2004/072081 (2004-08-01), None
patent: WO 2005/005429 (2005-01-01), None
patent: WO 2005/014599 (2005-02-01), None
patent: WO 2005/019220 (2005-03-01), None
patent: WO 2005/047290 (2005-05-01), None
Jeffery, Trina K., et al., “Phosphodiesterase III and V Inhibitors on Pulmonary Artery from Pulmonary Hypertensive Rats: Differences Between Early and Established Pulmonary Hypertension” Journal of Cardivascular Pharmacology 1998, vol. 32, No. 2, pp. 213-219.
Hanks, Steven K., “Hanks Classification” 1994, pp. 1-4 http://pkr.sdsc.edu/html/pk—catalytic/pk—hanks—class.html.
Lumma, William C., et al., “Piperazinylimidazo }1,2-alpyrazines with Selective Affinity for in Vitro—-Adrenergic Receptor Subtypes” J. Med. Chem. 1983, vol. 26, pp. 357-363.
Stenberg, Kaj A. E., et al., “KinMutBase, a database of human disease-causing protein kinase mutations” Nucleic Acids Research 2000, vol. 28, pp. 369-372.
Vitse, O. et al., “New Imidazo[1,2-a]pyrazine Derivatives with Bronchodilatory and Cyclic Nucleotide Phosphodiesterase Inhibitory Activities” Bioorganic & Medicinal Chemistry 1999, vol. 7, pp. 1059-1065.
Ding et al. (2002) “A Combinatorial Scaffold Approach toward Kinase-Directed Heterocycle Libraries,” J. Am. Chem. Soc., 124(8): 1594-1596.
“Protein Kinases in Disease,” references produced from a Sep. 24, 1997, search of the On-line Meddelian Inheritance in Man (OMIM) database, pp. 1-11, from http://bioinformatics.weizmann.ac.il/Kinases/pkr/pk—medicine.html.
International Search Report dated Oct. 22, 2003, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
Written Opinion dated Dec. 5, 2003, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
Second Written Opinion dated Apr. 13, 2004, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
International Preliminary Examination Report dated Aug. 3, 2004, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
International Search Report dated Feb. 9, 2004, for Application No. PCT/US03/28329, International filing date Sep. 9, 2003.
Written Opinion dated Jul. 6, 2004, for Application No. PCT/US03/28329, International filing date Sep. 9, 2003.
International Preliminary Examination Report dated Oct. 27, 2004, for Application No. PCT/US03/28329, International filing date Sep. 9, 2003.
International Search Report and Written Opinion dated Jul. 7, 2004, for Application No. PCT/US2004/003922, International filing date Feb. 10, 2004.
International Search Report and Written Opinion dated Jul. 7, 2004, Application No. PCT/US2004/003923, International filing date Feb. 10, 2004.
International Search Report and Written Opinion dated Dec. 8, 2004, for Application No. PCT/US2004/021150, International filing date Jun. 30, 2004.
International Search Report and Written Opinion dated Dec. 30, 2004, for Application No. PCT/US2004/018227, International filing date Jun. 4, 2004.
International Search Report and Written Opinion dated Feb. 1, 2005, for Application No. PCT/US2004/025884, International filing date Aug. 11, 2004.
Invitation to Pay Additional Fees with Partial International Search Report dated May 3, 2005, for Application No. PCT/US2004/037433, International filing date Nov. 10, 2004.
International Search Report and Written Opinion dated Jun. 23, 2005, for Application No. PCT/US2004/037433, International filing date Nov. 10, 2004.
Office Action dated Apr. 3, 2006, for U.S. Appl. No. 10/776,002, filed Feb. 10, 2004.
Notice of Allowance dated Aug. 11, 2006, for U.S. Appl. No. 10/776,002, filed Feb. 10, 2004.
Currie Kevin S.
Darrow James W.
DeSimone Robert W.
Mitchell Scott A.
Pippin Douglas A.
CGI Pharmaceuticals, Inc.
Tucker Zachary C.
LandOfFree
Certain 6, 8-(heteroaryl or aryl) disubstituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Certain 6, 8-(heteroaryl or aryl) disubstituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Certain 6, 8-(heteroaryl or aryl) disubstituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3813636